This story was originally published June 9.
Seattle-based Adaptive TCR, which provides immune repertoire sequencing services, has raised $5.8 million from private investors in a Series B investment round, the company reported last week.
The new financing adds to $4.5 million that the company secured last year, when it first launched its service (IS 7/20/2010).
This latest investment will be used to grow the company's immune system sequencing service, immunoSeq, and "invest in clinical applications in the oncology, autoimmune, and vaccine fields," CEO Chad Robins said in a statement.
According to Adaptive TCR, its platform can be used by biotech and pharmaceutical companies to predict whether patients will respond to certain therapeutics or vaccines. The company is currently testing its technology in a pilot program to sequence the T-cells and B-cells of volunteers, searching for marks of exposure to 17 different pathogens (CSN 4/12/2011).